Summary and Info
Recombinant protein drugs are intimately associated with the impressive success story of the Biotech Industry during the past thirty years, some of them belonging to the most successful pharmaceutical products. More than thirty different proteins are available for a variety of clinical applications, over 300 proteins are presently being evaluated in clinical trials. In this new volume of the MDT series, historical, technical and clinical aspects of recombinant protein drug discovery and development are presented, covering past, present and future highlights. Leading scientists and co-founders of early Biotech companies describe technical breakthroughs and the fascinating story of pioneering discoveries, as well as the long way of translating them into products and business. Therefore, this book represents an exciting documentation of the beginning of a new era in the pharmaceutical industry. In addition, scientists from basic research, clinic and industry actively involved in new developments discuss...
More About the Author
Charles Weissmann (born 14 October 1931) is a Hungarian-born Swiss molecular biologist. Weissmann is particularly known for the first cloning and expression of interferon and his contributions to the unraveling of the molecular genetics of neurogenerative prion diseases such as scrapie, Creutzfeldt–Jakob disease and "mad cow disease".
Review and Comments
Rate the Book
Recombinant Protein Drugs 0 out of 5 stars based on 0 ratings.